GlassScriptPhysician profile
Rachel Devarajulu
NPI 1699452193
$5,405.54
in general payments reported to CMS, 2019-2025
24 companies · $2,317 in 2025
The $2,317 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $698 · 2024: $2,391 · 2025: $2,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,393 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,393.39 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $853.60 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $614.63 | 2023-2025 | Caplyta |
| Alkermes, INC. | $511.29 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $452.00 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $443.19 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $438.84 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $432.36 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $271.72 | 2024-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $225.47 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $202.36 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $127.94 | 2023-2025 | Trintellix |
| Corium, LLC | $125.51 | 2024-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $122.27 | 2023-2025 | Invega Sustenna, Spravato |
| Indivior INC. | $115.09 | 2023-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $102.46 | 2024-2025 | Cobenfy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $100.08 | 2023-2024 | Jornay Pm |
| Tris Pharma INC | $75.35 | 2023-2025 | Dyanavel Xr |
| Luye Pharma (USA) LTD. | $58.03 | 2025 | Erzofri Extended-Release |
| Sage Therapeutics, LLC | $40.45 | 2025 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $32.52 | 2025 | Jornay Pm |
| Avion Pharmaceuticals | $16.28 | 2023 | Methylphenidate Hydrochloride |
| Vertical Pharmaceuticals, LLC | $15.96 | 2024 | Methylphenidate Hydrochloride |
| Braeburn INC. | $14.63 | 2025 | Brixadi |
| Noven Therapeutics, LLC | $13.51 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Devarajulu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.